Simmons Bank Has $3.50 Million Stock Holdings in Veeva Systems Inc. $VEEV

Simmons Bank increased its position in shares of Veeva Systems Inc. (NYSE:VEEV) by 9.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,151 shares of the technology company’s stock after acquiring an additional 1,099 shares during the period. Simmons Bank’s holdings in Veeva Systems were worth $3,499,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Crossmark Global Holdings Inc. acquired a new stake in shares of Veeva Systems during the 1st quarter worth approximately $299,000. Private Trust Co. NA boosted its position in shares of Veeva Systems by 35.0% during the 1st quarter. Private Trust Co. NA now owns 247 shares of the technology company’s stock worth $57,000 after acquiring an additional 64 shares in the last quarter. Merit Financial Group LLC boosted its position in Veeva Systems by 12.5% in the second quarter. Merit Financial Group LLC now owns 45,247 shares of the technology company’s stock valued at $13,030,000 after buying an additional 5,042 shares in the last quarter. QRG Capital Management Inc. boosted its position in Veeva Systems by 15.7% in the second quarter. QRG Capital Management Inc. now owns 12,771 shares of the technology company’s stock valued at $3,678,000 after buying an additional 1,735 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its position in Veeva Systems by 1.9% in the second quarter. Teacher Retirement System of Texas now owns 143,469 shares of the technology company’s stock valued at $41,316,000 after buying an additional 2,659 shares in the last quarter. Institutional investors and hedge funds own 88.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on VEEV shares. JPMorgan Chase & Co. upgraded shares of Veeva Systems from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $290.00 to $330.00 in a report on Monday, September 8th. BTIG Research reissued a “buy” rating and set a $340.00 target price on shares of Veeva Systems in a research note on Friday, October 17th. Wells Fargo & Company lifted their price target on shares of Veeva Systems from $300.00 to $326.00 and gave the company an “overweight” rating in a research note on Tuesday, August 26th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Veeva Systems in a research note on Wednesday, October 8th. Finally, UBS Group lifted their price objective on shares of Veeva Systems from $285.00 to $310.00 and gave the company a “neutral” rating in a report on Thursday, August 28th. Seventeen investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Veeva Systems currently has a consensus rating of “Moderate Buy” and an average price target of $307.58.

Insider Buying and Selling

In related news, insider Thomas D. Schwenger sold 3,350 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the sale, the insider owned 23,773 shares of the company’s stock, valued at approximately $7,132,850.92. This represents a 12.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Jonathan Faddis sold 720 shares of the company’s stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $298.12, for a total transaction of $214,646.40. Following the sale, the senior vice president directly owned 7,868 shares in the company, valued at $2,345,608.16. This trade represents a 8.38% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 24,665 shares of company stock valued at $7,438,000. Company insiders own 10.30% of the company’s stock.

Veeva Systems Stock Up 0.3%

VEEV opened at $293.67 on Wednesday. The stock has a market cap of $48.14 billion, a price-to-earnings ratio of 60.30, a PEG ratio of 2.22 and a beta of 0.98. Veeva Systems Inc. has a twelve month low of $201.54 and a twelve month high of $310.50. The company’s 50-day moving average price is $285.50 and its two-hundred day moving average price is $274.00.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.90 by ($0.64). The business had revenue of $789.08 million during the quarter, compared to the consensus estimate of $768.49 million. Veeva Systems had a net margin of 27.29% and a return on equity of 13.72%. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the firm earned $1.62 EPS. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. As a group, sell-side analysts anticipate that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.